Abstract 1851
Background
Immune checkpoint inhibitors can cause pneumonitis in lung cancer patients. The role of previous thoracic radiation therapy (TRT) as a risk factor is not clear. Furthermore, some patients show radiation recall pneumonitis (RRP) pattern. In this multicenter retrospective study, we analyzed the relationship of previous TRT and other potential risk factors with nivolumab-induced pneumonitis, and the characteristics of RRP.
Methods
Medical records of non-small cell lung cancer patients, who received nivolumab between December 2015 and March 2017, were retrospectively reviewed. Baseline clinical characteristics, incidence, and risk factors were analyzed at 5 hospitals. Person’s chi-square test and multivariate logistic regression analysis (age, sex, smoking history, treatment history of TRT, and performance status at the start of nivolumab treatment) were conducted to identify potential risk factors. Imaging analysis for RRP was conducted only for patients treated in National Cancer Center Hospital at the moment.
Results
A total of 669 patients were evaluated, and the incidences of all-grade and ≥ grade 2 pneumonitis were 8.9% (60/669) and 7.2% (47/669), respectively. Two (0.3%) patients died due to the pneumonitis. Incidences of pneumonitis were 12.9% (33/256) and 6.5% (27/413) in patients with and without previous TRT, respectively. History of previous TRT was associated with pneumonitis in multivariate analysis [odds ratio, 1.95; 95% confidence interval 1.13-3.34]. Chest imaging by computed tomography of some of those patients showed RRP pattern with pneumonitis infiltration occurring in the radiation field previously treated, and the direct relation was suggested. Incidences of RRP were 4.2% (4/95) among patients with history of previous TRT and 30.8% (4/13) among patients with previous TRT and who developed nivolumab-induced pneumonitis.
Conclusions
Increasing risk of nivolumab-induced pneumonitis was associated with treatment history of TRT. RRP pattern was one of the characteristic radiographic patterns of nivolumab-induced pneumonitis in patients with previous TRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5054 - Inhibition of Rspo-Wnt pathway Facilitates Checkpoint Blockade Therapy by anti-RSPO3 antibody (DBPR117)
Presenter: John Hsu
Session: Poster Display session 1
Resources:
Abstract
3305 - A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumors
Presenter: Jürgen Krauss
Session: Poster Display session 1
Resources:
Abstract
5353 - Phase 1/2 Study of 9-ING-41, a small molecule selective Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors
Presenter: Benedito Carneiro
Session: Poster Display session 1
Resources:
Abstract
3946 - Trial in progress: a Phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumors (NCT03447314).
Presenter: Aaron Hansen
Session: Poster Display session 1
Resources:
Abstract
3449 - Radiographic Phenotyping to Identify Intracranial Disseminated Recurrence in Brain metastases Treated With Radiosurgery Using Contrast-enhanced MR Imaging
Presenter: CheYu Hsu
Session: Poster Display session 1
Resources:
Abstract
4553 - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer
Presenter: Lijuan Chen
Session: Poster Display session 1
Resources:
Abstract
4942 - Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: a comparison of RECIST 1.1, RANO and iRANO criteria
Presenter: Emilie Le Rhun
Session: Poster Display session 1
Resources:
Abstract
3529 - Management of multiple brain metastases by Staged SRS focusing on utmost risk lesions
Presenter: shaoqun Li
Session: Poster Display session 1
Resources:
Abstract
5315 - Whole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer
Presenter: Lu Li
Session: Poster Display session 1
Resources:
Abstract
1116 - 3D based texture analysis serving as potential diagnostic factor in discriminating primary central nervous system lymphoma from metastatic brain tumors: A preliminary study
Presenter: Wen Guo
Session: Poster Display session 1
Resources:
Abstract